| 000 | 01789 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517044510.0 | ||
| 264 | 0 | _c20160512 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1471-230X | ||
| 024 | 7 |
_a10.1186/s12876-015-0320-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Sai | |
| 245 | 0 | 0 |
_aCost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. _h[electronic resource] |
| 260 |
_bBMC gastroenterology _cAug 2015 |
||
| 300 |
_a98 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 |
_aBenzimidazoles _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorenes _xeconomics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xeconomics |
| 650 | 0 | 4 |
_aMacrocyclic Compounds _xeconomics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRibavirin _xeconomics |
| 650 | 0 | 4 |
_aRitonavir _xeconomics |
| 650 | 0 | 4 |
_aSimeprevir _xeconomics |
| 650 | 0 | 4 |
_aSofosbuvir _xeconomics |
| 650 | 0 | 4 |
_aSulfonamides _xeconomics |
| 650 | 0 | 4 |
_aUracil _xanalogs & derivatives |
| 650 | 0 | 4 |
_aUridine Monophosphate _xanalogs & derivatives |
| 700 | 1 | _aBastian, Nathaniel D | |
| 700 | 1 | _aGriffin, Paul M | |
| 773 | 0 |
_tBMC gastroenterology _gvol. 15 _gp. 98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12876-015-0320-4 _zAvailable from publisher's website |
| 999 |
_c25136390 _d25136390 |
||